[1] 刘 青,王泰龄. 慢加急性肝衰竭(ACLF)共识纪要:亚太肝病学会推荐(APASL)[J]. 临床肝胆病杂志[J],2010,26(1):13-18.
[2] 刘海华,王锦权. 脓毒症致急性肾损伤发病机制和临床防治的研究进展[J]. 感染、炎症、修复,2009,10(2):126-128.
[3] Jay P Sanford. 热病——桑福德抗微生物治疗指南[M]. 范洪伟等译.44版. 北京:中国协和医科大学出版社,2015:211-213.
[4] 陈灏珠,林果为. 实用内科学[M].13版. 北京:人民卫生出版社,2012:2173-2174.
[5] Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill:challenges and potential solutions[J]. Lancet Infect Dis, 2014,14(6):498-509.
[6] Ulldemolins M, Soy D, Llaurado-Serra M, et al. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy:influence of residual diuresis on dose requirements[J]. Antimicrob Agents Chemother, 2015,59(9):5520-5528.
[7] 国家药典委员会. 中华人民共和国药典2015年版四部[S]. 北京:中国医药科技出版社,2015:118.
[8] Rowland M, Tozer TN. 临床药代动力学与药效动力学 [M]. 陈东生等译.4版. 北京:人民卫生出版社,2012:112.
[9] Williams MF, Dukes GE, Heizer W, et al. Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine[J]. Pharm Res,1992,9(9):1190-1194.
[10] 杨文琳,王美霞. 血液净化救治急性药物或毒物中毒[J]. 中国危重病急救医学,2005,17 (11):704-704.
[11] 尧国胜,李 军,黄 高,等. 急性重症中毒血液净化治疗的进展[J]. 右江民族医学院学报,2015,37(1):131-134.
[12] Rhodes NJ, MacVane SH, Kuti JL, et al. Impact of loading doses on the time to adequate predicted beta-lactam concentrations in prolonged and continuous infusion dosing schemes[J]. Clin Infect Dis, 2014,59(6):905-907.
[13] Luke DR, Wood ND, Tomaszewski KE, et al. Pharmacokinetics of sulfobutylether-b-cyclodextrin (SBECD) in subjects on hemodialysis[J]. Nephrol Dial Transplant,2012,27(3):1207-1212.
[14] Hafner V, Czock D, BurhenneJ, et al.Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration[J]. Antimicrob Agents Chemother, 2010,54(6):2596-2602.
[15] Kiser TH, Fish DN, Aquilante CL, et al.Evaluation of sulfobutylether-β-cyclodextrin (SBECD) accumulation and voriconazole pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy[J]. Crit Care, 2015,18(3):32-40.
[16] Turner RB, Martello JL, Malhotra A. Worsening renal function in patients with baseline renal impairment treated with intravenous voriconazole:A systematic review[J]. Int J Antimicrob Agents, 2015,46(4):362-366.
[17] Atiq F, van den Bemt PM, Leebeek FW, et al. A systematic review on the accumulation of prophylactic dosages of low-molecular-weight heparins (LMWHs) in patients with renal insufficiency[J]. Eur J Clin Pharmacol, 2015,71(8):921-929.
[18] Park D, Southern W, Calvo M, et al. Treatment with Dalteparin is associated with a lower risk of bleeding compared to treatment with unfractionated heparin in patients with renal insufficiency[J]. J Gen Lntern Med, 2016,31(2):182-187.